TargetMol

Tallimustine HCl

Product Code:
 
TAR-T68151L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T68151L-1mg1mg£227.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68151L-5mg5mg£416.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68151L-10mg10mg£581.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68151L-25mg25mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68151L-50mg50mg£1,163.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68151L-100mg100mg£1,540.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68151L-500mg500mg£3,026.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Tallimustine HCl is a DNA inhibitor, an AT-specific alkylated antitumor derivative of diamycin.Tallimustine HCl can be used in severe combined immunodeficiency mouse models of adult myelogenous leukemia, which can be used for the treatment of leukemia.
CAS:
118438-45-2
Molecular Weight:
734.08
Pathway:
DNA Damage/DNA Repair
Purity:
0.9852
SMILES:
Cl.O=C(NC=1C=C(C(=O)NC=2C=C(C(=O)NC=3C=C(C(=O)NCCC(=N)N)N(C3)C)N(C2)C)N(C1)C)C4=CC=C(C=C4)N(CCCl)CCCl
Target:
DNA

Documents

References

Erba E, et al. Comparison of cell-cycle phase perturbations induced by the DNA-minor-groove alkylator tallimustine and by melphalan in the SW626 cell line. Int J Cancer. 1995;62(2):170-175. Bianchi N, et al. Accumulation of gamma-globin mRNA and induction of erythroid differentiation after treatment of human leukaemic K562 cells with tallimustine. Br J Haematol. 2001;113(4):951-961. Tagliabue G, et al. Combination of the new minor groove alkylator tallimustine and melphalan. Eur J Cancer. 1997;33(2):284-287. Herzig MC, et al. Tallimustine lesions in cellular DNA are AT sequence-specific but not region-specific. Biochemistry. 1999;38(42):14045-14055.